Defender Capital’s Lifecore Biomedical LFCR Stock Holding History

Defender Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-86,450	Closed	-$535K	–	39
2023 Q4	$535K	Hold	86,450	–	–	0.19%	22
2023 Q3	$652K	Hold	86,450	–	–	0.24%	18
2023 Q2	$836K	Hold	86,450	–	–	0.29%	19
2023 Q1	$326K	Hold	86,450	–	–	0.11%	29
2022 Q4	$560K	Hold	86,450	–	–	0.23%	18
2022 Q3	$769K	Sell	86,450 -5,000	-5%	-$50.8K	0.3%	19
2022 Q2	$912K	Sell	91,450 -30,000	-25%	-$297K	0.36%	17
2022 Q1	$1.39M	Sell	121,450 -5,000	-4%	-$55.7K	0.48%	16
2021 Q4	$1.4M	Buy	126,450 +66,450	+111%	+$645K	0.45%	16
2021 Q3	$553K	Buy	60,000 +20,000	+50%	+$218K	0.18%	28
2021 Q2	$450K	Buy	40,000 +10,000	+33%	+$115K	0.15%	27
2021 Q1	$318K	Hold	30,000	–	–	0.11%	30
2020 Q4	$326K	Hold	30,000	–	–	0.14%	27
2020 Q3	$292K	Buy	+30,000	New	+$286K	0.14%	23

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Defender Capital's LFCR Position: Q1 2024 in Review

Defender Capital sold out of Lifecore Biomedical (LFCR) in Q1 2024, closing a stake of 86,450 shares — an estimated $535K sold.

Defender Capital first reported a position in LFCR in Q3 2020 and held it in 14 quarters. The position peaked at $1.4M in Q4 2021. 79 funds tracked by Wall St. Rank hold LFCR as of Q1 2024.

Defender Capital reported no remaining Lifecore Biomedical position as of Q1 2024 after selling out during the quarter.
Defender Capital sold 86,450 Lifecore Biomedical shares in Q1 2024, an estimated $535K.
Defender Capital first reported a position in Lifecore Biomedical in Q3 2020 and held it in 14 quarters.
Defender Capital's Lifecore Biomedical position peaked at $1.4M in Q4 2021.
79 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2024.

Based on Defender Capital's 13F filing for Q1 2024, filed 6 May 2024.